Source: Weill Cornell Medical College
Date: March 21, 2007
Summary:
A peptide developed by scientists at Weill Cornell Medical College may expand the availability and durability of islet cell transplant for patients with type-1 diabetes, which is characterized by a lack of these insulin-producing cells. The findings were recently published in the Journal of the American Society of Nephrology. The researchers say the current study is merely "proof of principle" that the peptide treatment might improve islet cell transplant. But the results are encouraging.
